Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol

Esto ha llevado a comparar su uso con el de otros tratamientos crnicos, como las estatinas, cuya eficacia depende de la administracin continua
Quantification was performed on three slides from each brain blinded to study group
Suliman M, Buckley A, Al Tikriti A, et al
Diabetes Ther 12 (1), 143157 (2021)
Some are shots, others are pills, some need to be taken daily, others weekly